Brain tumor vaccine has promising results

Nov 22, 2006

U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.

Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.

The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.

The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology.

Copyright 2006 by United Press International

Explore further: Police seize millions in huge fake Viagra swoop

add to favorites email to friend print save as pdf

Related Stories

Brain tumor vaccine trial shows promising results

Apr 16, 2007

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

Poll: Big Bang a big question for most Americans

Apr 21, 2014

Few Americans question that smoking causes cancer. But they have more skepticism than confidence in global warming, the age of the Earth and evolution and have the most trouble believing a Big Bang created the universe 13.8 ...

Climate conditions help forecast meningitis outbreaks

Mar 18, 2014

Determining the role of climate in the spread of certain diseases can assist health officials in "forecasting" epidemics. New research on meningitis incidence in sub-Saharan Africa pinpoints wind and dust ...

A tiny, time-released treatment

Oct 09, 2013

Omid Farokhzad's vision of medicine's future sounds a lot like science fiction. He sees medicine scaled down, with vanishingly small nanoparticles playing a big role, delivering drug doses measured in molecules ...

Study turns parasite invasion theory on its head

Dec 23, 2012

Current thinking on how the Toxoplasma gondii parasite invades its host is incorrect, according to a study published today in Nature Methods describing a new technique to knock out genes. The findings coul ...

Recommended for you

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0